FDA Approves Ozempic to Lower Chronic Kidney Disease Risks in Diabetes Patients
FDA Approves Ozempic for Chronic Kidney Disease Risk Reduction, Expanding Its Therapeutic Scope WASHINGTON — In a groundbreaking move, the U.S. Food and Drug Management (FDA) has approved Ozempic, the widely popular GLP-1 drug, for reducing risks associated with chronic kidney disease (CKD) in adults with Type 2 diabetes. This decision, announced Tuesday by … Read more